PMV Pharmaceuticals 3Q 2026: EPS ($0.52) — 10-Q Summary
PMV Pharmaceuticals reported a wider net loss of $34.37M in Q3 2026, with EPS at ($0.52), due to warrant remeasurement loss and offering costs. The company completed enrollment for a Phase 2 trial of rezatapopt and plans to submit an NDA in Q1 2027. Cash reserves totaled $108.5M, expected to last into Q1 2028.
How this was made
The 30-second read
Why it matters
The widened loss and negative EPS suggest short‑term downside, but the cash runway to 2028 may provide some support.
Market read
Earnings release for a micro‑cap biotech; new loss figures could move the stock.
Timing
post‑market today
Background
The article summarizes PMV Pharmaceuticals' Form 10‑Q filing for Q3 2026, highlighting financial and operational updates.
Ticker impact
Q3 net loss widened to $34.37M and diluted EPS of -$0.52, a fresh earnings disclosure.
likely pressure as the market prices in the widened loss
The company reported a larger loss than the prior year, which typically leads to a sell‑off in micro‑cap stocks.
Key entities
- companyPMV Pharmaceuticals
Biopharma developing rezatapopt for ovarian cancer.
